Venus Remedies promoters confirm zero pledged shares in FY26

1 min read Updated on 20 May 2026, 03:59 AM

Reviewed by

Suketu GScanX News Team

AI Summary

Venus Remedies Limited disclosed that its promoters and promoter group have not pledged or encumbered any shares as of March 31, 2026. The declaration, made under SEBI (SAST) Regulations, confirms no new encumbrances beyond prior disclosures for FY26.

*this image is generated using AI for illustrative purposes only.

Venus Remedies Limited has submitted a yearly disclosure to the stock exchanges confirming that its promoters and promoter group hold no encumbered or pledged shares. The declaration, dated April 4, 2026, was made in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The disclosure covers the financial year ended March 31, 2026. Pawan Chaudhary, Promoter and Managing Director, stated on behalf of the promoter group that they have not made or released any encumbrance of shares, directly or indirectly, other than those already disclosed to the exchanges. He further confirmed that as of March 31, 2026, no equity shares held by the promoters or the promoter group were encumbered or pledged.

The list of promoters and the promoter group included in the disclosure is detailed below:

Category	Name
Promoters
1	Pawan Chaudhary
2	Manu Chaudhary
Promoter Group
3	Peeyush Jain
4	Ashutosh Jain
5	Akshansh Chaudhary
6	Sunev Pharma Solutions Pvt Ltd

The communication was addressed to the National Stock Exchange of India Ltd. and BSE Limited. The company’s compliance officer, Neha, filed the disclosure on behalf of venus remedies .

Historical Stock Returns for Venus Remedies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.19%	+21.28%	+22.27%	+71.42%	+219.45%	+261.81%

How might Venus Remedies' clean pledge record influence institutional investor confidence and potential foreign portfolio investment in the company going forward?

Could the zero-encumbrance status of promoter shares signal upcoming capital raise plans or strategic acquisitions by Venus Remedies in the pharmaceutical sector?

How does Venus Remedies' promoter shareholding stability compare to peers in the mid-cap pharmaceutical space, and what competitive advantages might this provide during market volatility?

Read Next Article

Venus Remedies Schedules Board Meeting on May 26, 2026 to Approve Q4FY26 Financial Results

1 min read Updated on 15 May 2026, 06:50 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Venus Remedies Limited has intimated stock exchanges of a Board of Directors meeting on May 26, 2026, pursuant to Regulation 29 of SEBI (LODR) Regulations, 2015. The agenda includes approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, recommendation of final dividend, and AGM-related matters. The trading window for designated persons has been closed from April 1, 2026 until 48 hours after the declaration of financial results.

*this image is generated using AI for illustrative purposes only.

Venus Remedies Limited has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Tuesday, May 26, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated May 15, 2026, was submitted to both the National Stock Exchange of India Ltd. and BSE Limited.

Board Meeting Agenda

The board meeting has been convened to address several key matters. The following items are on the agenda for consideration:

Agenda Item:	Details
Financial Results:	Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026
Dividend Recommendation:	Final dividend for the year ended March 31, 2026, if any
AGM Matters:	Matters relating to the ensuing Annual General Meeting
Other Business:	Any other business with the permission of the Chair

Trading Window Closure

In compliance with the provisions of Prevention of Insider Trading, Venus Remedies has closed the trading window for designated persons with respect to trading in the company's shares. The closure is effective from April 1, 2026, and will remain in force until 48 hours after the declaration of the financial results. This measure is intended to ensure that designated persons do not trade in company securities while in possession of unpublished price-sensitive information.

The intimation has also been uploaded on the company's official website at www.venusremedies.com . The filing was digitally signed on May 15, 2026.

Historical Stock Returns for Venus Remedies

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+2.19%	+21.28%	+22.27%	+71.42%	+219.45%	+261.81%

How might Venus Remedies' FY2026 annual financial results compare to its previous year's performance, and what revenue growth trajectory can investors expect?

Will Venus Remedies declare a final dividend for FY2026, and how does its dividend history suggest the likelihood and potential quantum of any payout?

What strategic announcements or management guidance might emerge from the AGM that could signal Venus Remedies' expansion plans in the pharmaceutical sector?